Results 61 to 70 of about 4,942 (259)

Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology, 2023
Aims: As the impact of inclisiran in stroke prevention in atherosclerotic cardiovascular disease (ASCVD) patients or those at high risk of ASCVD is still unclear, we conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to
Min Luo, Yihan Liu, Yihan Liu, Xinyi Xu, Xinyi Xu, Kai Liu, Chao Shen, Haoyang Hu, Zhiyao He, Fengbo Wu   +9 more
doaj   +1 more source

Inclisiran: Efficacy in Real World-Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Background: Inclisiran is a novel lipid-lowering agent targeting PCSK9 via small interfering RNA (siRNA) technology. While clinical trials such as the ORION studies have demonstrated significant reductions in low-density lipoprotein cholesterol (c-LDL ...
Alaíz ÁR, Gudino LC, de la Isla LP, Pardo HG, Calle DG, Miramontes-González JP.   +5 more
europepmc   +2 more sources

Inclisiran: a new pharmacological approach to the treatment of hypercolesterolemia and mixed dyslipidemia [PDF]

, 2023
Introducere. Dislipidemia mixta, hipercolesterolemia primară și secundară se caracterizează prin niveluri crescute de colesterol LDL, care în lipsa tratamentului poate duce la complicații premature și deces din cauza dezvoltării accelerate a bolii ...
Gavriliuc, Svetlana, Sasu, Diana, Stoica, Mihaela, Sârbu, Oxana   +3 more
core  

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders

Российский кардиологический журнал, 2023
The novelty of the 2023 National Guidelines for Lipid Metabolism Disorders is presented regarding the categorization of cardiovascular risk, target and optimal levels of blood lipids, diagnosis and therapeutic approaches to the treatment of dyslipidemia.
I. V. Sergienko, M. V. Ezhov
doaj   +1 more source

Using RNAi in the treatment of cardiovascular diseases - therapeutics based on siRNA overview [PDF]

, 2022
RNA interference (RNAi) discovered in the 1990s by Fire and Mello plays a role in silencing gene function. One type of RNAi is siRNA, which is a double-stranded molecule of 20-25 base pairs.
Rusinowska, Barbara
core   +1 more source

The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis

Frontiers in Pharmacology
Objective: Statin is well-established as a classical lipid-lowering drug, and its cost has reduced considerably in the past years. Inclisiran is a new and effective lipid-lowering drug given as a subcutaneous injection at 6-month intervals.
Wenjing Zhou, Zhuoru Liang, Xiaohuan Lou, Nansong Wang, Xinyu Liu, Ruoxi Li, Pearl Pai, Pearl Pai   +7 more
doaj   +1 more source

The Effects of Inclisiran on the Subclinical Prothrombotic and Platelet Activation Markers in Patients at High Cardiovascular Risk. [PDF]

J Cardiovasc Dev Dis
Atherosclerosis as a multifactorial disease remains the first cause of death worldwide. Current oral lipid-lowering drugs (especially statins) reduce low-density lipoprotein cholesterol (LDLC) levels in the blood, but their clinical efficacy seems to be ...
Maligłówka M, Dec A, Bułdak Ł, Okopień B.   +3 more
europepmc   +2 more sources

Inclisiran in Cardiovascular Health: A Review of Mechanisms, Efficacy, and Future Prospects. [PDF]

Med Sci Monit
Dyslipidemia is a significant risk factor for cardiovascular disease, and managing low-density lipoprotein cholesterol levels is a crucial strategy for both the prevention and treatment of cardiovascular disease.
Huang F, Dai Q, Zhou Y, Guan J, Wu J, Dong Y, Lv J.   +6 more
europepmc   +2 more sources

RNA‐Based Therapies for Inherited Metabolic Disorders

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Inherited metabolic disorders (IMDs) are a diverse and complex group of genetic conditions resulting from deficiencies in enzymes, transporters, or cofactors. These deficiencies lead to metabolic dysfunction and severe clinical consequences. Despite significant progress in understanding their molecular basis, treatment options remain limited ...
Reddy Sreekanth Vootukuri, Sonam Gurung, Roopkatha Ghosh, Philippa B. Mills, Julien Baruteau, Haiyan Zhou   +5 more
wiley   +1 more source

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Frontiers in Cardiovascular Medicine, 2021
Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with ...
Chandni Bardolia, Nishita Shah Amin, Jacques Turgeon, Jacques Turgeon   +3 more
doaj   +1 more source